ASCO 2022 – Standing ovation and hope. - Cerba Research
CACSV
Breast cancer biomarkers, and a new clinical category for HER2 expression | Medical Laboratory Observer
HER2 spectrum of expression according to ASCO/CAP guidelines. HER2-low... | Download Scientific Diagram
Oncology Times
Le linee guida ASCO/CAP 2018
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows | BMC Medical Genomics | Full Text
Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents - Modern Pathology
PPT - HER2 Testing in Breast Cancer: 2013 ASCO/CAP HER2 Guideline Update PowerPoint Presentation - ID:6109259
What's New in the 2020 Update to the CAP/ASCO ER/PR Testing Guidelines in Breast Cancer?
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.,JAMA Oncology - X-MOL
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/ CAP ISH group 4 breast cancer | npj Breast Cancer
Q&A column - CAP TODAY
Second act for HER2, in gastric cancers - CAP TODAY
Updated (2018) ASCO/CAP Guidelines for HER2 Testing in Breast Cancer - Insights
PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar
ASCO-CAP HER2 Test Guideline Recommendations PDF | PDF | Immunohistochemistry | Metastasis
PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar
Introduction:
ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia - ScienceDirect